Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 27 09 2018
revised: 21 12 2018
accepted: 06 01 2019
pubmed: 5 2 2019
medline: 2 11 2019
entrez: 5 2 2019
Statut: ppublish

Résumé

It is currently unknown whether increasing radiation therapy (RT) volume has a negative impact on the health-related quality of life (HRQoL) of patients with low-grade glioma in the short term. The aim was to examine whether the size of the target volume is independently associated with HRQoL. We included patients who were treated with radiation therapy in the European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 study and who completed baseline HRQoL assessment. HRQoL was measured at baseline and every 3 months thereafter until progression, using the European Organisation for Research and Treatment of Cancer quality of life and brain cancer module questionnaires (QLQ-C30 and QLQ-BN20). We investigated whether there were associations between radiation volumes and (changes in) 4 preselected HRQoL scales (global health status, cognitive and social functioning, and fatigue). Also, we determined if radiation volumes were independently associated with a change in HRQoL over time. We included 195 of 240 patients (81.3%) randomized to radiation therapy in this analysis. The brain volume receiving radiation therapy was not associated with (changes in) HRQoL during the first 24 months after radiation therapy. Over time, radiation volumes were also not independently associated with HRQoL. Notably, the occurrence of tumor progression was found to be associated with worse functioning and more fatigue. The brain target volume receiving focal radiation therapy in fractions of 1.8 Gy to a total of 50.4 Gy did not appear to be independently associated with HRQoL in high-risk patients with low-grade glioma in the short term, as opposed to tumor progression. However, the impact of radiation volumes on long-term HRQoL, as well as neurocognitive functioning, remains to be investigated.

Identifiants

pubmed: 30716525
pii: S0360-3016(19)30038-0
doi: 10.1016/j.ijrobp.2019.01.003
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-100

Subventions

Organisme : Cancer Research UK
ID : 6850
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Linda Dirven (L)

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.

Jaap C Reijneveld (JC)

Department of Neurology and Brain Tumor Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Martin J B Taphoorn (MJB)

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.

Corneel Coens (C)

Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.

Samy A El-Badawy (SA)

Department of Radiation Oncology, National Cancer Institute, Cairo, Egypt.

Tzahala Tzuk-Shina (T)

Department of Oncology, Rambam Health Care Campus, Oncology Institute, Haifa, Israel.

Jose Bravo-Marques (J)

Department of Neurology, Instituto Portugues de Oncologia de Lisboa, Lisbon, Portugal.

Michael Back (M)

Northern Sydney Cancer Center, Royal North Shore Hospital, Sydney, Australia.

Lukas J A Stalpers (LJA)

Department of Radiotherapy, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Roger Stupp (R)

Malnati Brain Tumor Institute of the Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States.

Brigitta G Baumert (BG)

Department of Radiation Oncology (MAASTRO Clinic) and GROW (School for Oncology and Developmental Biology), Maastricht University Medical Center, Maastricht, The Netherlands; Department of Radiation Oncology, University Bonn Medical Center, Bonn, Germany.

Clemens Seidel (C)

Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Leipzig, Leipzig, Germany. Electronic address: Clemens.Seidel@medizin.uni-leipzig.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH